Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Anti-OX40 Antibody KHK4083 in Moderate to Severe Atopic Dermatitis
2018-000998-72Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rocatinlimab in atopic dermatitis (AD) (5 arms), sponsored by Kyowa Kirin. Primary endpoint: Percent change from baseline to Week 16 in EASI score. Started Jul 2018; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000998-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000998-72.